VIR (Vir Biotechnology) EPS (Basic) : $-3.82 (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Vir Biotechnology EPS (Basic)?

Vir Biotechnology's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was $-0.76. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.82.

Vir Biotechnology's EPS (Diluted) for the three months ended in Dec. 2024 was $-0.76. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-3.82.

Vir Biotechnology's EPS without NRI for the three months ended in Dec. 2024 was $-0.78. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -3.55.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Vir Biotechnology's highest 3-Year average EPS without NRI Growth Rate was -19.90% per year. The lowest was -51.60% per year. And the median was -35.75% per year.

Vir Biotechnology EPS (Basic) Historical Data

The historical data trend for Vir Biotechnology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vir Biotechnology EPS (Basic) Chart

Vir Biotechnology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-2.51

4.07

3.89

-4.59

-3.83

Vir Biotechnology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.86	-0.48	-1.02	-1.56	-0.76

Vir Biotechnology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Vir Biotechnology's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-521.96	-	0)	/	136.247
	=	-3.83

Vir Biotechnology's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-104.589	-	0)	/	136.809
	=	-0.76

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.82

Vir Biotechnology (NAS:VIR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Vir Biotechnology EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Vir Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vir Biotechnology Inc (NAS:VIR) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1800 Owens Street, Suite 900, San Francisco, CA, USA, 94158

Website

https://www.vir.bio

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Executives

Ann M. Hanly	officer: Chief Technology Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
George A Scangos	director, officer: President and CEO	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Backer Marianne De	officer: Chief Executive Officer	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Vicki L Sato	director	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Janet Napolitano	director	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Sung Lee	officer: Chief Financial Officer	7000 MARINA BLVD, BRISBANE CA 94005
Phillip Pang	officer: Chief Medical Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Svf Endurance (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008
Steven J. Rice	officer: Chief Administrative Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Johanna Friedl-naderer	officer: Chief Business Officer, Global	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Howard Horn	officer: CFO	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Charles Elliott Sigal	director	32 BREARLY ROAD, PRINCETON NJ 08540
Herbert Virgin	officer: EVP, Research & CSO	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Robert J More	director	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001